Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients.

PLoS One

Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia ; HemaCore LLC, Moscow, Russia ; Lomonosov Moscow State University, Moscow, Russia ; National Research Center for Hematology, Health Ministry RF, Moscow, Russia ; Center for Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences, Moscow, Russia.

Published: October 2014

Background And Objective: Using an in vitro experimental model of immobilized tissue factor-initiated clot growth in platelet-free plasma (thrombodynamics), we observed formation of activator-independent isolated spontaneous clots (SC) throughout the plasma volume in patients with cardiac infarction, acute leukemia, hemolytic anemia, and some other disorders. The aim of this work was to characterize this phenomenon and to identify the mechanisms of SC formation.

Methods And Results: Tissue factor inhibitor (VIIai) prevented SC in only 2 out of 23 patient plasma samples. Specific inhibitors of factors IXa and XIa were efficient in all 8 cases that we tested. Also, only factors IXa and XIa added to normal donors' plasma induced SC formations from isolated centers, in a pattern similar to that in patients' plasma. In contrast, factors VIIa, Va, tissue factor induced uniform plasma clotting. SC disappeared after high-speed centrifugation. However, phospholipid supplementation of centrifuged plasma returned them at least partially in 5 out of 22 patients' plasmas, indicating some other role of microparticles than providing phospholipid surface. Circulating procoagulant microparticles isolated from plasma directly activated factor XII in buffer and in diluted plasma. Flow cytometry revealed an increase in procoagulant microparticles in patients' plasmas with SC.

Conclusion: Our data suggest that combination of circulating active factors (specifically, factors IXa and XIa) with circulating procoagulant and contact-pathway-activating microparticles is the predominant mechanism causing spontaneous clotting in patient plasma.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909194PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087692PLOS

Publication Analysis

Top Keywords

factors ixa
16
ixa xia
16
plasma
11
contact-pathway-activating microparticles
8
spontaneous clotting
8
tissue factor
8
patient plasma
8
patients' plasmas
8
circulating procoagulant
8
procoagulant microparticles
8

Similar Publications

Article Synopsis
  • Dysregulation of BDNF is linked to Alzheimer's disease, and this study examined its expression in the hippocampus of 5xFAD mice, focusing on sex and age.
  • At 3 months, female wild-type mice had higher Bdnf mRNA levels than males, but this difference disappeared in female 5xFAD mice.
  • By 6 months, female 5xFAD mice showed a significant decrease in full-length TrkB receptor mRNA while increased levels of truncated TrkB were observed in both sexes, highlighting potential disruptions in BDNF signaling due to Alzheimer's.
  • The research indicates that certain Bdnf splice variants are maintained at higher levels in young female mice but may be affected by Alzheimer's
View Article and Find Full Text PDF

Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors.

J Thromb Thrombolysis

December 2024

Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, 70125, USA.

Article Synopsis
  • FXIIa is a plasma protease in the contact activation pathway, and inhibiting it could lead to safer anticoagulation treatments without the bleeding risks of current options.!* -
  • The study tested an amidine-containing molecule (inhibitor 1) and found it primarily inhibits human FXIIa with an IC value of ~30 µM, while showing variable selectivity against other factors involved in blood coagulation.!* -
  • Inhibitor 1 effectively prolongs clotting time in plasma without significant cytotoxicity, making it a promising candidate for further development as a safer anticoagulant for thromboembolic diseases.!*
View Article and Find Full Text PDF

Thrombotic disorders pose a global health threat, emphasizing the urgent need for effective management strategies. This study explores the potential of bioactive compounds derived from guava leaves in inhibiting coagulation factor IXa (CFIXa) using methods. Using GC-MS, bioactive compounds extracted from guava leaf through ethanol maceration were identified.

View Article and Find Full Text PDF

This study investigated the intraspecific and interspecific variability in the venom effects of viperid snake species and subspecies (eleven venoms total) on plasma clotting times, fibrinogen levels, and fibrin clot strength. Significant delays in plasma clotting time were observed for , , , , , and . Notably, the phylogenetically disjunct lineages , , and exhibited the most potent anticoagulant effects, indicating the independent amplification of a basal trait.

View Article and Find Full Text PDF

Coagulation factor IX plays a central role in hemostasis through interaction with factor VIIIa to form a factor X-activating complex at the site of injury. The absence of factor IX activity results in the bleeding disorder hemophilia B. This absence of activity can arise either from a lack of circulating factor IX protein or mutations that decrease the activity of factor IX.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!